Therapeutic potential of cell-penetrating peptides

Therapeutic Delivery

Volumn 4, Issue 5, 2013, Pages 573-591

  Vasconcelos, Luís ^a   Pärn, Kalle ^b   Langel, Ülo ^a,b  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

AM 111; AMINOCAPROIC ACID; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; AVI 5038; AVI 5126; AZX 100; CECROPIN A; CELL PENETRATING PEPTIDE; CYCLOSPORIN A; DOXORUBICIN; DTS 108; HEPARIN BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAI 1678; KAI 9083; METHOTREXATE; PACLITAXEL; PENETRATIN; PLACEBO; PROTEGRIN; PROTEIN P28; RT 001; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; XG 102;

ABSENCE OF SIDE EFFECTS; ALLODYNIA; ALPHA HELIX; AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CELL TRANSPORT; CHEMICAL MODIFICATION; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DUCHENNE MUSCULAR DYSTROPHY; ENDOCYTOSIS; ENDOSOME; ENZYME INHIBITION; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; HEARING IMPAIRMENT; HUMAN; HYPERHIDROSIS; INFLAMMATION; KELOID; LIPID RAFT; MALIGNANT NEOPLASTIC DISEASE; NEUROPROTECTION; PINOCYTOSIS; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; REVIEW; SOLID TUMOR; SPINAL CORD INJURY;

EID: 84877671384     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.22     Document Type: Review

References (159)

1. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl Acad. Sci. USA 88(5), 1864-1868 (1991
2. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55(6), 1189-1193 (1988
3. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269(14), 10444-10450 (1994
4. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272(25), 16010-16017 (1997
5. Pooga M, Hällbrink M, Zorko M, Langel Ü. Cell penetration by transportan. FASEB J. 12(1), 67-77 (1998
6. Futaki S, Suzuki T, Ohashi W et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276(8), 5836-5840 (2001
7. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl Acad. Sci. USA 97(24), 13003-13008 (2000
8. Andaloussi SE, Lehto T, Mager I et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 39(9), 3972-3987 (2011
9. Nasrollahi SA, Taghibiglou C, Azizi E, Farboud ES. Cell-penetrating peptides as a novel transdermal drug delivery system. Chem. Biol. Drug Des. 80(5), 639-646 (2012
10. Jones AT, Sayers EJ. Cell entry of cell penetrating peptides: tales of tails wagging dogs. J. Control. Release 161(2), 582-591 (2012
11. Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 61(9), 704-709 (2009
12. Grdisa M. The delivery of biologically active (therapeutic) peptides and proteins into cells. Curr. Med. Chem. 18(9), 1373-1379 (2011
13. Stewart KM, Horton KL, Kelley SO. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org. Biomol. Chem. 6(13), 2242-2255 (2008
14. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60(2), 249-271 (2000
15. Zhang Y, Yu LC. Single-cell microinjection technology in cell biology. Bioessays 30(6), 606-610 (2008
16. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand. 177(4), 437-447 (2003
17. Dalby B, Cates S, Harris A et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33(2), 95-103 (2004
18. Kingston RE, Chen CA, Okayama H. Calcium phosphate transfection. Curr. Protoc. Immunol. Chapter 10, Unit 10.13 (2001
19. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157(2), 195-206 (2009
20. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 62(16), 1839-1849 (2005
21. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 10(7), 290-295 (2000
22. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21(2), 45-48 (2000
23. Lebleu B, Robbins I, Bastide L, Vives E, Gee JE. Pharmacokinetics of oligonucleotides in cell culture. Ciba Found. Symp. 209, 47-54; discussion 54-49 (1997
24. Futaki S, Hirose H, Nakase I. Arginine-rich peptides: methods of translocation through biological membranes. Curr. Pharm. Des. 19(16), 2863-2868 (2012
25. Jones SW, Christison R, Bundell K et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br. J. Pharmacol. 145(8), 1093-1102 (2005
26. Chen L, Wright LR, Chen CH, Oliver SF, Wender PA, Mochly-Rosen D. Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem. Biol. 8(12), 1123-1129 (2001
27. Valero J, Van Gool M, Perez-Fernandez R et al. Non-peptidic cell-penetrating agents: synthesis of oligomeric chiral bicyclic guanidinium vectors. Org. Biomol. Chem. 10(28), 5417-5430 (2012
28. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH. The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev. 60(4-5), 452-472 (2008
29. Rothbard JB, Jessop TC, Wender PA. Molecular understanding of cellular uptake by arginine-rich cell penetrating peptides. In: Polymeric Drug Delivery I: Particulate Drug Carriers (volume 923), Svenson S (Ed.). American Chemical Society, DC, USA, 166-181 (2006
30. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277(33), 30208-30218 (2002
31. Murphy JE, Uno T, Hamer JD, Cohen FE, Dwarki V, Zuckermann RN. A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery. Proc. Natl Acad. Sci. USA 95(4), 1517-1522 (1998
32. Nur EKMS, Kamal JM, Qureshi MM, Maruta H. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation. Oncogene 18(54), 7787-7793 (1999
33. Kamide K, Nakakubo H, Uno S, Fukamizu A. Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications. Int. J. Mol. Med. 25(1), 41-51 (2010
34. McKeown AN, Naro JL, Huskins LJ, Almeida PF. A thermodynamic approach to the mechanism of cell-penetrating peptides in model membranes. Biochemistry 50(5), 654-662 (2011
35. Lindberg M, Jarvet J, Langel Ü, Graslund A. Secondary structure and position of the cell-penetrating peptide transportan in SDS micelles as determined by NMR. Biochemistry 40(10), 3141-3149 (2001
36. Dathe M, Schumann M, Wieprecht T et al. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 35(38), 12612-12622 (1996
37. Scheller A, Oehlke J, Wiesner B et al. Structural requirements for cellular uptake of alpha-helical amphipathic peptides. J. Pept. Sci. 5(4), 185-194 (1999
38. Futaki S. Membrane permeable basic peptides: the potential of these peptides for the intracellular delivery of proteins and drugs. Tanpakushitsu Kakusan Koso 47(11), 1415-1419 (2002
39. Czajlik A, Mesko E, Penke B, Perczel A. Investigation of penetratin peptides. Part 1. The environment dependent conformational properties of penetratin and two of its derivatives. J. Pept. Sci. 8(4), 151-171 (2002
40. Magzoub M, Eriksson LE, Graslund A. Conformational states of the cell-penetrating peptide penetratin when interacting with phospholipid vesicles: effects of surface charge and peptide concentration. Biochim. Biophys. Acta 1563(1-2), 53-63 (2002
41. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27(2), 85-131 (2004
42. Amand HL, Fant K, Norden B, Esbjorner EK. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem. Biophys. Res. Commun. 371(4), 621-625 (2008
43. Kichler A, Leborgne C, Marz J, Danos O, Bechinger B. Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells. Proc. Natl Acad. Sci. USA 100(4), 1564-1568 (2003
44. Fei L, Zaro J, Shen Wc. Acid-labile modification of a cell penetrating peptide for use in a targeted drug delivery. Presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. Los Angeles, CA, USA, 8-12 November 2009
45. Lehto T, Ezzat K, Langel U. Peptide nanoparticles for oligonucleotide delivery. Prog. Mol. Biol. Transl Sci. 104, 397-426 (2011
46. Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr. Pharm. Des. 14(24), 2415-2447 (2008
47. Kim YW, Grossmann TN, Verdine GL. Synthesis of all-hydrocarbon stapled alpha-helical peptides by ring-closing olefin metathesis. Nat. Protoc. 6(6), 761-771 (2011
48. Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122(24), 5891-5892 (2000
49. Richard JP, Melikov K, Vives E et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278(1), 585-590 (2003
50. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10(3), 310-315 (2004
51. Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther. 8(2), 284-294 (2003
52. Raagel H, Saalik P, Hansen M, Langel Ü, Pooga M. CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway. J. Control. Release 139(2), 108-117 (2009
53. Fittipaldi A, Ferrari A, Zoppe M et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278(36), 34141-34149 (2003
54. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 280(15), 15300-15306 (2005
55. Mager I, Langel K, Lehto T, Eiriksdottir E, Langel Ü. The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. Biochim. Biophys. Acta 1818(3), 502-511 (2012
56. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8(7), 848-866 (2007
57. Ezzat K, Helmfors H, Tudoran O et al. Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J. 26(3), 1172-1180 (2012
58. Lindberg S, Munoz-Alarcon A, Helmfors H et al. PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors. Int. J. Pharm. 441(1-2), 242-247 (2013
59. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J. Biol. Chem. 284(49), 33957-33965 (2009
60. Mano M, Teodosio C, Paiva A, Simoes S, Pedroso De Lima MC. On the mechanisms of the internalization of S4(13)-PV cell-penetrating peptide. Biochem. J. 390(Pt 2), 603-612 (2005
61. Watkins CL, Schmaljohann D, Futaki S, Jones AT. Low concentration thresholds of plasma membranes for rapid energy-independent translocation of a cell-penetrating peptide. Biochem. J. 420(2), 179-189 (2009
62. Maniti O, Blanchard E, Trugnan G, Lamaziere A, Ayala-Sanmartin J. Metabolic energy-independent mechanism of internalization for the cell penetrating peptide penetratin. Int. J. Biochem. Cell Biol. 44(6), 869-875 (2012
63. Lamaziere A, Burlina F, Wolf C, Chassaing G, Trugnan G, Ayala-Sanmartin J. Non-metabolic membrane tubulation and permeability induced by bioactive peptides. PLoS ONE 2(2), e201 (2007
64. El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 11(1), 13-22 (2009
65. Nakase I, Kobayashi S, Futaki S. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Biopolymers 94(6), 763-770 (2010
66. Hällbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel Ü. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 1515(2), 101-109 (2001
67. Cheung JC, Kim Chiaw P, Deber CM, Bear CE. A novel method for monitoring the cytosolic delivery of peptide cargo. J. Control. Release 137(1), 2-7 (2009
68. Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel Ü. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 21(11), 2664-2671 (2007
69. Gooding M, Browne LP, Quinteiro FM, Selwood DL. siRNA delivery: from lipids to cell-penetrating peptides and their mimics. Chem. Biol. Drug Des. 80(6), 787-809 (2012
70. Margus H, Padari K, Pooga M. Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol. Ther. 20(3), 525-533 (2012
71. Crombez L, Morris MC, Dufort S et al. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 37(14), 4559-4569 (2009
72. Morris MC, Gros E, Aldrian-Herrada G et al. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res. 35(7), e49 (2007
73. Xia H, Gao X, Gu G et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 32(36), 9888-9898 (2011
74. Ganguly S, Chaubey B, Tripathi S et al. Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element. Oligonucleotides 18(3), 277-286 (2008
75. Rothbard JB, Garlington S, Lin Q et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6(11), 1253-1257 (2000
76. Govindarajan S, Sivakumar J, Garimidi P et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Biomaterials 33(8), 2570-2582 (2012
77. Nakase I, Konishi Y, Ueda M, Saji H, Futaki S. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J. Control. Release 159(2), 181-188 (2012
78. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285(5433), 1569-1572 (1999
79. Tan M, Lan KH, Yao J et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 66(7), 3764-3772 (2006
80. Kondo E, Saito K, Tashiro Y et al. Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat. Commun. 3, 951 (2012
81. Hayashi Y, Yamauchi J, Khalil IA, Kajimoto K, Akita H, Harashima H. Cell penetrating peptide-mediated systemic siRNA delivery to the liver. Int. J. Pharm. 419(1-2), 308-313 (2011
82. Suhorutsenko J, Oskolkov N, Arukuusk P et al. Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconj. Chem. 22(11), 2255-2262 (2011
83. Zorko M, Langel Ü. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57(4), 529-545 (2005
84. Berglund P, Fleeton MN, Smerdou C, Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17(5), 497-507 (1999
85. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2(2), E36 (2004
86. Amantana A, Moulton HM, Cate ML et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18(4), 1325-1331 (2007
87. Lee HJ, Pardridge WM. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug. Chem. 12(6), 995-999 (2001
88. Lebleu B, Moulton HM, Abes R et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 60(4-5), 517-529 (2008
89. Sarko D, Beijer B, Garcia Boy R et al. The pharmacokinetics of cell-penetrating peptides. Mol. Pharm. 7(6), 2224-2231 (2010
90. Fawell S, Seery J, Daikh Y et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl Acad. Sci. USA 91(2), 664-668 (1994
91. Bullok KE, Dyszlewski M, Prior JL, Pica CM, Sharma V, Piwnica-Worms D. Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with (99m)Tc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy. Bioconjug. Chem. 13(6), 1226-1237 (2002
92. Kameyama S, Okada R, Kikuchi T et al. Distribution of immunoglobulin Fab fragment conjugated with HIV-1 REV peptide following intravenous administration in rats. Mol. Pharm. 3(2), 174-180 (2006
93. Kameyama S, Horie M, Kikuchi T et al. Effects of cell-permeating peptide binding on the distribution of 125I-labeled Fab fragment in rats. Bioconjug. Chem. 17(3), 597-602 (2006
94. Jarver P, Langel Ü. Cell-penetrating peptides - a brief introduction. Biochim. Biophys. Acta 1758(3), 260-263 (2006
95. Madigan MT, Madigan MT, Brock TD. Brock biology of microorganisms (12th Edition). Pearson/Benjamin Cummings, CA, USA (2009
96. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55(1), 27-55 (2003
97. Zhu WL, Shin SY. Effects of dimerization of the cell-penetrating peptide Tat analog on antimicrobial activity and mechanism of bactericidal action. J. Pept. Sci. 15(5), 345-352 (2009
98. Zhu WL, Hahm KS, Shin SY. Cell selectivity and mechanism of action of short antimicrobial peptides designed from the cell-penetrating peptide Pep-1. J. Pept. Sci. 15(9), 569-575 (2009
99. Palm C, Netzereab S, Hällbrink M. Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects. Peptides 27(7), 1710-1716 (2006
100. Jung HJ, Park Y, Hahm KS, Lee DG. Biological activity of Tat (47-58) peptide on human pathogenic fungi. Biochem. Biophys. Res. Commun. 345(1), 222-228 (2006
101. Nekhotiaeva N, Elmquist A, Rajarao GK, Hällbrink M, Langel Ü, Good L. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J. 18(2), 394-396 (2004
102. Bahnsen JS, Franzyk H, Sandberg-Schaal A, Nielsen HM. Antimicrobial and cell-penetrating properties of penetratin analogs: effect of sequence and secondary structure. Biochim. Biophys. Acta 1828(2), 223-232 (2013
103. Masman MF, Rodriguez AM, Raimondi M et al. Penetratin and derivatives acting as antifungal agents. Eur. J. Med. Chem. 44(1), 212-228 (2009
104. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 126(31), 9506-9507 (2004
105. Bartlett RL 2nd, Sharma S, Panitch A. Cell-penetrating peptides released from thermosensitive nanoparticles suppress pro-inflammatory cytokine response by specifically targeting inflamed cartilage explants. Nanomedicine 9(3), 419-427 (2012
106. Wang YF, Xu X, Fan X et al. A cell-penetrating peptide suppresses inflammation by inhibiting NF-kappaB signaling. Mol. Ther. 19(10), 1849-1857 (2011
107. Heo K, Kim JS, Kim K et al. Cell-penetrating H4 tail peptides potentiate p53-mediated transactivation via inhibition of G9a and HDAC1. Oncogene doi:10.1038/onc.2012.273 (2012) (Epub ahead of print
108. Savariar EN, Felsen C, Nashi N et al. Real time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell penetrating peptides. Cancer Res. 73(2), 855-864 (2013
109. Hearst SM, Walker LR, Shao Q, Lopez M, Raucher D, Vig PJ. The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration. Neuroscience 197, 369-380 (2011
110. Meade AJ, Meloni BP, Mastaglia FL, Watt PM, Knuckey NW. AP-1 inhibitory peptides attenuate in vitro cortical neuronal cell death induced by kainic acid. Brain Res. 1360, 8-16 (2010
111. Manno I, Antonucci F, Caleo M, Bozzi Y. BoNT/E prevents seizure-induced activation of caspase 3 in the rat hippocampus. Neuroreport 18(4), 373-376 (2007
112. Johnson RM, Harrison SD, Maclean D. Therapeutic applications of cell-penetrating peptides. Methods Mol. Biol. 683, 535-551 (2011
113. Sho ED J, Jin, Z, Begley, R, Chen L, Harrison SD, Mendel DB. Protein kinase C-δ inhibitor protects against ischemic stroke by inhibing cellular injury and inflammation and promoting astrocyte proliferation. Presented at: International Stroke Conference 2008. New Orleans, LA, USA, February 20-22, 2008
114. Miao FJP, Mohammad HK, Velazquez KT, Harrison SD, Sweitzer SM. KAI-1678, a novel inhibitor of protein kinase C epsilon, attenuates hyperalgesia and allodynia in three neuropathic pain models in rodents. Presented at: Neuroscience 2008. Washington, DC, USA, 15-19 November 2008
115. Hirt L, Badaut J, Thevenet J et al. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 35(7), 1738-1743 (2004
116. Wang J, Van De Water TR, Bonny C, De Ribaupierre F, Puel JL, Zine A. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J. Neurosci. 23(24), 8596-8607 (2003
117. Meyer-Losic F, Nicolazzi C, Quinonero J et al. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin. Cancer Res. 14(7), 2145-2153 (2008
118. Lee JK, Park SC, Hahm KS, Park Y. Antimicrobial HPA3NT3 peptide analogs: placement of aromatic rings and positive charges are key determinants for cell selectivity and mechanism of action. Biochim. Biophys. Acta 1828(2), 443-454 (2012
119. Li L, Shi Y, Su G, Le G. Selectivity for and destruction of Salmonella typhimurium via a membrane damage mechanism of a cell-penetrating peptide ppTG20 analogue. Int. J. Antimicrob. Agents 40(4), 337-343 (2012
120. Holm T, Bruchmann J, Scheynius A, Langel Ü. Cell-penetrating peptides as antifungals towards Malassezia sympodialis. Lett. Appl. Microbiol. 54(1), 39-44 (2012
121. Garibotto FM, Garro AD, Rodriguez AM et al. Penetratin analogues acting as antifungal agents. Eur. J. Med. Chem. 46(1), 370-377 (2011
122. Arrighi RB, Ebikeme C, Jiang Y et al. Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrob. Agents Chemother. 52(9), 3414-3417 (2008
123. Liu Y, Xia X, Xu L, Wang Y. Design of hybrid beta-hairpin peptides with enhanced cell specificity and potent anti-inflammatory activity. Biomaterials 34(1), 237-250 (2013
124. Keogan S, Passic S, Krebs FC. Infection by CXCR4-tropic human immunodeficiency virus type 1 is inhibited by the cationic cell-penetrating peptide derived from HIV-1 Tat. Int. J. Pept. 2012, 349427 (2012
125. Steel R, Cowan J, Payerne E, O'Connell MA, Searcey M. Anti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2/ Keap1 interaction. ACS Med. Chem. Lett. 3(5), 407-410 (2012
126. Lee JY, Seo YN, Park HJ, Park YJ, Chung CP. The cell-penetrating peptide domain from human heparin-binding epidermal growth factor-like growth factor (HB-EGF) has anti-inflammatory activity in vitro and in vivo. Biochem. Biophys. Res. Commun. 419(4), 597-604 (2012
127. Shah PP, Desai PR, Channer D, Singh M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J. Control. Release 161(3), 735-745 (2012
128. Wang Y, Li Y, Shan J, Fixman E, Mccusker C. Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell-penetrating peptide. Clin. Exp. Allergy 41(11), 1622-1630 (2011
129. Brugnano JL, Chan BK, Seal BL, Panitch A. Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides. J. Control. Release 155(2), 128-133 (2011
130. Kim J, Choi YL, Vallentin A et al. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 68(16), 6831-6839 (2008
131. Ren Y, Hauert S, Lo JH, Bhatia SN. Identification and characterization of receptor-specific peptides for siRNA delivery. ACS Nano 6(10), 8620-8631 (2012
132. Jiang T, Zhang Z, Zhang Y et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 33(36), 9246-9258 (2012
133. Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J. Control. Release 162(1), 225-232 (2012
134. Walker L, Perkins E, Kratz F, Raucher D. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int. J. Pharm. 436(1-2), 825-832 (2012
135. Mäe M, Rautsi O, Enbäck J et al. Tumour targeting with rationally modified cell-penetrating peptides. Int. J. Pept. Res. Ther. 18(4), 361-371 (2012
136. Simon MJ, Kang WH, Gao S, Banta S, Morrison B 3rd. Increased delivery of TAT across an endothelial monolayer following ischemic injury. Neurosci. Lett. 486(1), 1-4 (2010
137. Abes R, Arzumanov AA, Moulton HM et al. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem. Soc. Trans. 35(Pt 4), 775-779 (2007
138. Sazani R, Weller D, Leow S, Kole R, Shrewsburry S. AVI 5038: initial efficacy and safety evaluation in cynomolgus monkeys. Presented at: Treat-NMD/NIH Conference. Brussels, Belgium, 17-19 November 2009
139. Velazquez KT, Miao FJP, Mohammad HK, Ogden CJ, Harrison SD, Sweitzer SM. KAI-1678, a novel inhibitor of protein kinase C epsilon, attenuates mechanical hyperalgesia in rodent models of acute nociceptive, inflammatory and postsurgical pain. Presented at: Neuroscience 2008. Washington, DC, USA, 15-19 November 2008
140. Omotehara Y, Hakuba N, Hato N, Okada M, Gyo K. Protection against ischemic cochlear damage by intratympanic administration of AM-111. Otol. Neurotol. 32(9), 1422-1427 (2011
141. Brandt F, O'Connell C, Cazzaniga A, Waugh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol. Surg. 36(Suppl. 4), 2111-2118 (2010
142. Lopes LB, Furnish EJ, Komalavilas P et al. Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. J. Invest. Dermatol. 129(3), 590-598 (2009
143. Warso MA, Richards JM, Mehta D et al. A first in class, first in human, phase I trial of p28, a non-HDM2 mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. Br. J. Cancer 108, 1061-1070 (2013
144. Innovative RNA-based technology; first-in-class therapeutics. www.sareptatherapeutics.com/about/
145. Safety and efficacy study of AVI-5126 when used on vein grafts before use in heart by-pass graft surgery (CABG). www.clinicaltrials.gov/ct2/show/ NCT004512 56?term=avi+5126&rank=1
146. Duchenne Muscular Dystrophy - drug candidates/clinical trials. www.sareptatherapeutics.com/our-programs/ rare-diseases/duchenne-muscular- dystrophy/
147. Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. http://wwwext.amgen.com/about/amgen.html
148. ClinicalTrial Database: NCT000931. www.clinicaltrials.gov/ct2/show/ NCT000931 97?term=kai+9803&rank=1
149. Study of KAI-1678. www.clinicaltrials.gov/ct2/results?term=KAI- 1678&Search=Search
150. ClinicalTrial Database: NCT01570205. www.clinicaltrials.gov/ct2/show/ NCT01570205?term=xg+102&rank=1
151. Xigen raises $20 million. www.fiercebiotech.com/press-releases/ xigen-raises-20million
152. Leveraging development across multiple therapeutic applications. www.revance.com/products/pipeline.html
153. ClinicalTrial Database: NCT00907387. www.clinicaltrials.gov/ct2/show/ NCT00907387?term=Rt001&rank=2
154. AZX100 mode of action. www.capstonethx.com/research-development/ azx100modeofaction.php
155. ClinicalTrial Database: NCT00825916. www.clinicaltrials.gov/ct2/show/ NCT00825916?term=AZX100&rank=2
156. Mechanism of action of p28, a first in class, non-HDM2 mediated peptide inhibitor of p53 ubiquitination. www.cdgti.com/clinical-publication.asp
157. ClinicalTrial Database: NCT009149. www.clinicaltrials.gov/ct2/show/ NCT009149 14?term=CDG+Therapeutics&rank=1
158. ClinicalTrial Database: NCT00802425. www.clinicaltrials.gov/ct2/show/ NCT00802 425?term=NCT00802425&rank=1
159. AM-111, treatment of acute sensorineural hearing loss. www.aurismedical.com/p/therapies/am-111. php?lg=en